<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F020A7F9-89FC-44F4-A464-B104C04E9042"><gtr:id>F020A7F9-89FC-44F4-A464-B104C04E9042</gtr:id><gtr:name>Ablatus Therapeutics Limited</gtr:name><gtr:address><gtr:line1>1 St James Court, Whitefriars</gtr:line1><gtr:city>Norwich</gtr:city><gtr:postCode>NR3 1RU</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F020A7F9-89FC-44F4-A464-B104C04E9042" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>F020A7F9-89FC-44F4-A464-B104C04E9042</gtr:id><gtr:name>Ablatus Therapeutics Limited</gtr:name><gtr:address><gtr:line1>1 St James Court, Whitefriars</gtr:line1><gtr:city>Norwich</gtr:city><gtr:postCode>NR3 1RU</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>289209.0</gtr:offerGrant><gtr:projectCost>413156.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11DCEFE3-137A-4795-BAF3-A85D8DDAA210" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>11DCEFE3-137A-4795-BAF3-A85D8DDAA210</gtr:id><gtr:name>Eg Technology Limited</gtr:name><gtr:address><gtr:line1>Farfield House Albert Road, Stow-Cum-Quy</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB25 9AR</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>154722.0</gtr:offerGrant><gtr:projectCost>221032.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/776FB0BE-FC18-4F2B-B6B7-FA39C4B27ABE"><gtr:id>776FB0BE-FC18-4F2B-B6B7-FA39C4B27ABE</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Brooks</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=103351"><gtr:id>870C3A1F-3079-4166-B078-CAFA07767748</gtr:id><gtr:title>Bimodal Electric Tissue Ablation - Next Generation Radiofrequency Ablation</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>103351</gtr:grantReference><gtr:abstractText>BETA is the next generation of radiofrequency ablation medical device, providing a minimally invasive method for destroying cancerous tissue. It will revolutionise the approach to non-resectable liver metastases, allowing for the non-invasive treatment of large volume with low recurrence risk within patients. BETA is the result of 10 years of academic research, and will significantly improve the provision of medicine in the UK. BETA presents a wide range of benefits, both to patients and trusts including: a minimally invasive treatment approach (removing surgical risk and improving recovery times) and a low treatment cost. Further BETA will make RFA suitable for a wider range of treatment procedures including non-oncology applications such as gynaecology indications and varicose veins. In supporting the development of BETA from a research prototype to a certified medical device, IUK funding will give patients within the UK access to cutting-edge treatment techniques and an improved provision of healthcare.</gtr:abstractText><gtr:fund><gtr:end>2019-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2017-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>443931</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">103351</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>